Trials / Unknown
UnknownNCT00048217
A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Trimeris · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients who complete study T1249-102 (must be currently failing a T-20 containing regimen to participate in this study) will receive T-1249 at a dose of 200mg daily in combination with a background antiretroviral regimen for 96 weeks. Only patients that participated in study T1249-102 can participate in study T1249-105.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | T-1249 |
Timeline
- First posted
- 2002-10-30
- Last updated
- 2005-06-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00048217. Inclusion in this directory is not an endorsement.